Sharp Mesa Vista Hospital is enrolling both men and women ages 55 to 85 for studies of investigational medicines for Alzheimer's disease. To qualify, you must:

• Attend study visits at Sharp Mesa Vista Hospital's Clinical Research Center
• Have a caregiver (spouse, relative or health care aide) who can accompany you to study visits and help monitor your study progress

Clinical trial for individuals at high risk for Alzheimer's.

EARLY-AD — this study is designed for individuals who are currently not experiencing symptoms of memory loss, but are at a high risk for Alzheimer's disease due to age and/or genetics (such as having a first-degree relative with Alzheimer's disease). The study is looking at the efficacy and safety of an oral investigational drug in slowing cognitive decline. Participation in the study will last about four and a half years to carefully monitor cognitive and memory functioning.

Mild cognitive impairment clinical trials.

MISSION-AD — this study is designed for individuals with early Alzheimer's disease or mild cognitive impairment. The study is investigating the efficacy and safety of an oral investigational drug on symptoms of Alzheimer's disease. Study participation lasts approximately two years.

Mild Alzheimer's clinical trials.

NAVIGATE-AD — a study for people who have been experiencing worsening memory problems, or who may have been diagnosed with mild Alzheimer’s disease. As Alzheimer’s disease progresses, a protein called amyloid-beta builds up inside the brain. The NAVIGATE-AD study will ask what effect an oral investigational study drug has on the protein build up and on clinical symptoms of Alzheimer’s disease. Learn more about this study.

DAYBREAK-ALZ — the study is also for individuals who have been experiencing worsening memory problems or who have been diagnosed with mild Alzheimer's disease. The oral investigational drug will contain either a lower dose of the study drug, a higher dose of the study drug, or a placebo, depending on which group you are assigned to. Learn more about this study.

ReCOGNITION — this study is for people currently taking medication to treat mild Alzheimer's disease. Study will last for six months, and participants will receive one of three doses of either the study drug (Piromelatine) or a placebo. Participants will continue taking their prescribed medication during the study. The study will determine if Piromelatine will improve slow wave sleep and, additionally, will also improve memory and limit the effects of Alzheimer's. Learn more about this study.

How to enroll.

To learn more or to enroll in a clinical trial, call 858-836-8350 or send us an email.